BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 12917517)

  • 1. Phosphodiesterase 5 inhibitors in male sexual dysfunction.
    Kuthe A
    Curr Opin Urol; 2003 Sep; 13(5):405-10. PubMed ID: 12917517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction.
    Mason RG
    J R Soc Promot Health; 2003 Jun; 123(2):79-80. PubMed ID: 12852189
    [No Abstract]   [Full Text] [Related]  

  • 3. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
    Gresser U; Gleiter CH
    Eur J Med Res; 2002 Oct; 7(10):435-46. PubMed ID: 12435622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase-5 inhibitors: clinical market and basic science comparative studies.
    McCullough A
    Curr Urol Rep; 2004 Dec; 5(6):451-9. PubMed ID: 15541215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.
    Briganti A; Salonia A; Deho' F; Zanni G; Barbieri L; Rigatti P; Montorsi F
    World J Urol; 2005 Dec; 23(6):374-84. PubMed ID: 16273417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.
    Vickers MA; Satyanarayana R
    Int J Impot Res; 2002 Dec; 14(6):466-71. PubMed ID: 12494279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial comment on the manuscript entitled 'Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction'.
    Perimenis P
    Expert Opin Pharmacother; 2005 Jan; 6(1):1-2. PubMed ID: 15709877
    [No Abstract]   [Full Text] [Related]  

  • 8. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
    Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic update: treatment of erectile dysfunction in the elderly with phosphodiesterase type 5 inhibitors: cardiovascular implications.
    Agarwal P; Sander GE; Giles TD
    Am J Geriatr Cardiol; 2004; 13(6):332-5. PubMed ID: 15538074
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction.
    Kloner RA
    Circulation; 2004 Nov; 110(19):3149-55. PubMed ID: 15533876
    [No Abstract]   [Full Text] [Related]  

  • 11. [How effective are PDE-5 inhibitors?].
    Jünemann KP
    Urologe A; 2003 Apr; 42(4):553-8. PubMed ID: 12715127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
    J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression.
    Tsai BM; Turrentine MW; Sheridan BC; Wang M; Fiore AC; Brown JW; Meldrum DR
    Ann Thorac Surg; 2006 Jan; 81(1):272-8. PubMed ID: 16368379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
    Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY
    J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of ED: PDE-5 Inhibitors.
    Shabsigh R
    Endocrine; 2004; 23(2-3):135-41. PubMed ID: 15146092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil.
    Pomara G; Morelli G; Pomara S; Taddei S; Ghiadoni L; Dinelli N; Travaglini F; Dicuio M; Mondaini N; Salvetti A; Selli C
    J Androl; 2004; 25(4):625-9. PubMed ID: 15223851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel PDE5 inhibitors for the treatment of male erectile dysfunction.
    Kalsi JS; Bahadur G; Muneer A; Ozturk O; Christopher N; Ralph DJ; Minhas S
    Reprod Biomed Online; 2003; 7(4):456-61. PubMed ID: 14656408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus.
    Vardi M; Nini A
    Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD002187. PubMed ID: 17253475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors.
    Carson CC
    Am J Cardiol; 2005 Dec; 96(12B):37M-41M. PubMed ID: 16387565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral drug treatment of erectile dysfunction.
    Int J Impot Res; 2003 Dec; 15 Suppl 7():S27-9. PubMed ID: 14695970
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.